Purchase Order HHSN312201700009P

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $20,269.44 on September 21, 2017, with an ultimate completion date of October 31, 2017. Place of performance is San Diego, California. The order is firm fixed price with no set-aside applied. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $24,418.80 on November 30, 2018. The order is firm fixed price with no set-aside and carries an ultimate completion date of December 28, 2018. Place of performance is San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on May 3, 2018, with an ultimate completion date of June 4, 2018. Performance takes place in San Diego, California. The order procures sequencing reagents, consumables, or related bioinformatics products. No set-aside applies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on April 2, 2018, with completion scheduled for May 2, 2018. Work is performed in San Diego, California. The order is firm fixed price with no set-aside category applied. The source does not specify the particular equipment, reagents, consumables, or services procured under this order.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $13,512.96 on June 29, 2018, with an ultimate completion date of July 27, 2018. Work is performed in San Diego, California. The order covers DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software. No set-aside was used.</p>

<p>The National Institute of Neurological Disorders and Stroke awarded a purchase order to Illumina, Inc. valued at $16,189.27 on July 31, 2018, with ultimate completion on July 30, 2019. The order is firm fixed price with no set-aside. Work is performed in San Diego, California. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core offerings to federal health and research agencies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $13,250.00 on October 29, 2019, with an ultimate completion date of October 28, 2020. Work is performed in San Diego, California. The order is a firm fixed-price purchase for sequencing reagents, consumables, or related instrumentation—Illumina's core product line sold to NIH institutes and other federal research agencies. No set-aside applies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $15,314.69 on July 31, 2018, with final completion by August 29, 2018. The order is firm fixed price with no set-aside. Performance occurs in Bethesda, Maryland. The purchase order procures sequencing reagents, consumables, or related bioinformatics products from Illumina's core portfolio of DNA and RNA sequencing supplies and software.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $16,285.00 on November 17, 2017, with an ultimate completion date of November 17, 2018. Place of performance is San Diego, California. The order covers DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software. No set-aside category was used.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $13,419.16 on July 25, 2018, with ultimate completion on August 8, 2018. Work is performed in San Diego, California. The order procures sequencing reagents, consumables, or related bioinformatics products on a firm fixed price basis. No set-aside category was applied.</p>